SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 2, 1995
IMMUNOMEDICS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-12104 61-1009366
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
300 American Road, Morris Plains, New Jersey 07950
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code: (201) 605-8200
(Former name or former address, if changed since last report)
<PAGE>
Item 5. Other Events
The information contained in Exhibit 99 is incorporated here
by reference.
Item 7. Financial Statement and Exhibits
(c) Exhibits
Exhibit 99 - Press Release, dated October 2, 1995
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf
by the undersigned thereunto duly authorized.
IMMUNOMEDICS, INC.
By: /s/ Amy Factor
Amy Factor
Executive Vice President
Date: October 2, 1995
Contact:
Amy Factor, Executive Vice President
(201) 605-8200
FOR IMMEDIATE RELEASE
IMMUNOMEDICS COMPLETES $10 MILLION FINANCING
Morris Plains, NJ, October 2, 1995 -- Immunomedics, Inc.
(Nasdaq:IMMU) announced today that it completed the sale of 200,000
shares of non-dividend-paying Convertible Preferred Stock to several
foreign investors for $10 million. This financing transaction was
completed pursuant to Regulation S under the Securities Act of 1933.
The terms of the transaction allow the investors, at their discretion,
to convert the Preferred Stock into shares of the Company's Common
Stock during a pre-determined period subject to extension. The
conversion price will be based on pre-determined discounts of up to 9
3/4% from the average market price per share over a 30-day trading
period surrounding the dates conversion notices are received.
The securities being offered will not be or have not been registered
under the Securities Act and may not be offered or sold in the United
States absent registration or an applicable exemption from registration
requirements.
Immunomedics is a biopharmaceutical company applying innovative
technology in antibody selection, modification and chemistry to the
development of products for the detection and treatment of cancer and
infectious diseases. Integral to these products are highly specific,
humanized monoclonal antibodies designed to deliver radioisotopes and
chemotherapeutic agents to tumors and sites of infectious or other
diseases. The Company's colorectal cancer imaging agent, CEA-Scan ,
is under review for marketing approval by the U.S. Food and Drug
Administration, as well as by regulatory agencies in Europe and Canada.
The Company's infectious disease imaging agent, LeukoScan , is under
European regulatory review. In addition, Immunomedics currently has
a therapeutic product and several other diagnostic imaging products in
clinical trials.
